The short term fetal cardiovascular effects of corticosteroids used in obstetrics

Abstract

Background: Corticosteroids are widely used in obstetrics due to their striking effect on perinatal morbidity and mortality of premature neonates. Despite this, relatively few studies have explored short term fetal effects of corticosteroids as measured by ultrasound.

Objectives: 1) To present a literature review of short term fetal cardiovascular effects of corticosteroids 2) To describe the protocol of a current observational study (SUPER-A*STEROID) of cardiovascular effects of dexamethasone and betamethasone in the first week after their administration. This trial is nested within the A*STEROID blinded multicentre randomised controlled trial of the two steroid preparations.

Findings: Existing data suggest corticosteroids have little effect on the major measured fetal blood vessels when the baseline ultrasound is normal. In the compromised fetus, where the umbilical artery end-diastolic flow is abnormal prior to maternal corticosteroids, flow is temporarily restored in approximately 50% of cases. Whether such changes are beneficial is uncertain. Very little data exist that directly compare the short-term effects of betamethasone and dexamethasone. The SUPER-A*STEROID study described will help provide this information.

Keywords: antenatal corticosteroids, Doppler ultrasound, Myocardial Performance Index, premature delivery.

Introduction

It is known that antenatal maternal corticosteroid administration greatly reduces neonatal death, respiratory distress syndrome, and intraventricular haemorrhage rates in preterm infants.1 Steroid administration to mothers at high risk of preterm delivery < 34 weeks gestation is therefore part of routine clinical practice. As 70–80% of developed world pregnancies delivering at 24–34 weeks gestation receive steroids,2 in Australia alone at least 5000 steroid courses would be expected to be given each year prior to preterm birth. In reality fetal exposure to exogenous corticosteroids may be much higher, as many mothers receive corticosteroids for risk of preterm birth but deliver > 34 weeks. Additionally, many more women may be given steroids at later gestation when elective caesarean section without labour is planned.

Despite the many pregnancies exposed to corticosteroids, short-term effects of maternal steroid administration on fetal cardiovascular status are still uncertain. Whether the effects seen are beneficial, particularly in the growth-restricted fetus, is also controversial.

Interpretation of short-term fetal corticosteroid effects is made more difficult by the varying ways in which they can be studied, for example

- Type of steroid (betamethasone vs. dexamethasone)
- Baseline Doppler measurements (normal vs. abnormal)
- Indication for steroids
- Fetal vessel (UA, DV , MCA)
- Gestation given.

Existing work suggests that baseline umbilical artery end-diastolic velocity has significant impact on ultrasound measures of steroid effects, with type of steroid also potentially important.3 Table 1 summarises studies (of predominantly or exclusively singleton fetuses) examining corticosteroid effects in fetuses where baseline umbilical artery flows were normal.4–16 Although the methodologies of the included studies are mixed, cumulatively they show no consistent evidence of changes in velocity waveform patterns after corticosteroid administration in multiple arteries studied. Middle cerebral artery (MCA) pulsatility index is a possible exception, with changes at 48–72 hours noted in a minority of studies.3

Table 2 summarises short term data on effect of corticosteroids on fetal vessels in fetuses with abnormal umbilical artery (UA) diastolic blood flow pre-steroids. Most of these studies show a reduction of placental vascular resistance and temporary restoration of umbilical artery end-
diastolic velocities (UAEDF) after betamethasone administration. However, the proportion of cases with restored UAEDF ranges widely, from 33 to 100%.\textsuperscript{4,9,17–24} If UAEDF is restored this occurs rapidly: as early as 4–8 hours and definitely by 24 hours post-steroid administration.\textsuperscript{22} This suggests direct fetoplacental unit circulatory effects of steroids rather than cellular effects on transcription factors. As changes in uterine artery (UtA) flows are not seen post-steroid, the UA changes are most likely from direct steroid action on the fetal cardiovascular system.\textsuperscript{4}

There is wide variability in how long the effect of steroids on UAEDF lasts, with up to 7–10 days reported.\textsuperscript{23} However the median time at which the baseline abnormality returns is 3 days after the first dose of steroid.\textsuperscript{9,22,23} Other effects on the fetal circulation have not been consistently reported for this group, although decreased MCA PI (accentuating the MCA redistribution pattern seen in the growth restricted fetus) is reported by a minority of authors (Table 2).

Data is scant regarding UAEDF effects in multiple pregnancy. However, Barkehall-Thomas and colleagues\textsuperscript{25} found 50% rate of return of positive UAEDF after betamethasone administration

### Table 1: Studies describing short-term corticosteroid effects on blood flows with positive umbilical artery end-diastolic velocities at baseline.

| First author (year) | Regimen (dose: interval-hours) | Study design (measurement interval: hour) | Patients total (% IUGR) | Umbilical artery flow effects | MCA (PI) | DV (PI) | Uterine artery (PI) | Other blood vessels (PI: comments) |
|---------------------|--------------------------------|------------------------------------------|------------------------|------------------------------|-----------|---------|---------------------|----------------------------------|
| Thuring (4) (2011)  | Betamethasone 12 mg x 2: 24 hours apart | T0, 48, 96                              | 18 (70)                | ↓ PI 48h, return by 96h      | Non-sig   | ↓ PI 48h by 96h     | °                                 |
| Piazze (5) (2007)   | Betamethasone 12 mg x 2: q24hr | T0, 72, 96, 120                          | 84 (0)                 | °                            | ↓ PI 72h  | °                   | °                                 |
| Urban (2005) (6)    | Betamethasone 12 mg x 2: q24hr Dexamethasone 6 mg x 4: q12hr | T0, 24, 72 for both                  | 33 (0)                 | °                            | °         | °                   | °                                 |
| Kahler (2004) (7)   | Betamethasone 8 mg x 2: q24hr | T0, 32, 48, 72, 96                      | 27 (0)                 | °                            | °         | °                   | °                                 |
| Wijnberger (2004) (8) | Betamethasone 12 mg x 2: q24hr | T-120-0, T24-120 (variable)             | 55 (100)               | ° (NB high PI at baseline)  | Non-sig   | °                   | °                                 |
| Simchen (2004) (9)  | Betamethasone 12 mg x 2: q24hr | T0, 24, 48, 72                          | 6 (0)                  | °                            | °         | °                   | °                                 |
| Deren (2001) (10)   | Betamethasone 12 mg x 2: q24hr | T0, 24, 48, 72, 96, 120                 | 35 (0)                 | °                            | °         | °                   | °                                 |
| Piazze (2001) (11)  | Betamethasone 12 mg x 2: q24hr | T-48 to 0, 72, 120                      | 36 (28)                | °                            | ↓ PI 72hr | °                   | °                                 |
| Senat (2000) (12)   | Betamethasone 6 mg x 4: q12hr Dexamethasone 4 mg x 4: q12hr for both | T0, 48-96, 168                   | 25 incl. 10 twins (92)  | °                            | °         | °                   | °                                 |
| Rotmensch (1999) (16) | Betamethasone 12 mg x 2: q24hr | T0, 48, 96                              | 31 (0)                 | °                            | °         | °                   | °                                 |
| Cohlen (1996) (13)  | Betamethasone 12 mg x 2: q24hr | T0, 48, 96                              | 15 (7)                 | °                            | °         | °                   | °                                 |
| Meizner (1989) (14) | Betamethasone 12 mg x 2: q24hr | T0, 24, 48, 72                          | 18 (0)                 | °                            | °         | °                   | °                                 |
| Chitrit (2000) (15) | Dexamethasone 4 mg x 6: q8hr | T0, 48, 96, 168                         | 26 (0)                 | °                            | ↓ PI 96h  | °                   | °                                 |

\textsuperscript{°} = no change - = not measured in this study
CA = cerebral arteries other than MCA
Dao = Descending Aorta
ICA = Internal carotid artery
RA = Renal artery
PI= pulsatility index
T0= Baseline (pre-steroids)
MCA = Middle cerebral artery
DV = Ductus venosus
IUGR = Intrauterine growth restriction
Table 2: Studies describing short-term corticosteroid effects on blood flows with abnormal baseline umbilical artery end-diastolic velocities.

| First author (year) | Regimen (dose: interval) | Study design (measurement interval: hour) | Patients Total n (% IUGR) | Baseline UA abnormality | Umbilical artery flow effects | MCA (PI) | DV (PI) | Uterine artery (PI) | Other blood vessels (PI: comments) |
|---------------------|--------------------------|------------------------------------------|---------------------------|------------------------|-----------------------------|----------|---------|-------------------|-----------------------------------|
| Piazze (2012) (17)  | Betamethasone 12 mg X 2: q24hr | T0, then q24 until delivery | 64 (100) | AREDF | +EDF 24hr 21 (33%) | - | - | - | - |
| Thuring (2011) (4)  | Betamethasone 12 mg x 2: 24 hours apart | T0, T48, T96 | 15 (70) | AEDF 11 REDF 4 | 10 +EDF 48hr (2 REDF AEDF Return by 96hr) | Non-sig | | | |
| Nozaki (2009) (18)  | Betamethasone 12 mg x 2: 24 hours apart | T0, T24, T48 | 32 (100) | AEDF all | 22 (69%) +EDF 24h | ° | | | |
| Robertson (2009) (19)| Betamethasone 11.4 mg x 2:24 hours apart | T0 then variable (retrospective study) | 92 (100) | AEDF all | 58 (63%) "transient" +EDF post-steroid | - | - | - | - |
| Simchen (2004) (9)  | Betamethasone 12 mg x 2: q24hr | T0, 24, 48, 72 | 19 (100) | AREDF | 10 (53%) +EDF 24h, gone by 72hr | ° | - | - | UV velocity D1 if persistent AREDF |
| Muller (2003) (20)  | Betamethasone 8 mg x 1 Dexamethasone 12 mg x 1 | T0, 24–48 for both | 3 (100) 17 (100) | 13 AEDF and 7 REDF of total group (results not grouped by steroid) | 9 (45%) improvement at 24–48hr (7 to +ve flow, 2 REDF to AEDF) | 24h | ° | - | - |
| Edwards (2003) (21) | Betamethasone 11.4 mg x 2: q24h | T0, 12, 24, 48–240 | 55 (100)* | AEDF all | 39 (71%) +EDF 24hr: median return AEDF 72hr | - | - | - | - |
| Edwards (2002) (22) | Betamethasone 11.4 mg x 2:24 hours apart | T0 and 24 (all), some also T4, 8, 12 | 12 (100) | AEDF all | 12 (100%) +EDF 8–24h | 24h | ° | - | Renal artery * |
| Wijnberger (1999) (24) | Betamethasone 12 mg x 2: q24hr | T0, 24, 48, 72, 96 | 45 (100) | "redistribution" UA | ° | - | - | - | - |
| Wallace (1999) (23)  | Betamethasone 11.4 mg x 2:24 hours apart | T0, 24, 48, 72, 96 | 28 (100) | AEDF all | 19 (68%) +EDF 24 hrs: median return AEDF 72hr | - | - | - | - |

* = no change - = not measured in this study
* Includes 30 prospective patient and 25 singletons from the retrospective 1999 Wallace, et al. study: results pooled
UA = Umbilical artery
PI= pulsatility index
T0= Baseline (pre-steroids)
MCA = Middle cerebral artery
DV = Ductus venosus
UV = Umbilical vein
AEDF = Absent end-diastolic flow
EDF = End-diastolic flow
IUGR = Intrauterine growth restriction
in a mixed cohort of DCDA twins, MCDA twins, and triplets, suggesting hemodynamic effects of steroid administration are similar to singletons. More recently however, Chang and colleagues found that in only four of twenty MCDA twin pregnancies with UAEDF in one twin did EDF transiently return after betamethasone administration.

Whether the effects observed by ultrasound on fetal hemodynamics represent a beneficial boost to fetal circulation, or a potential harmful over-riding of compensation mechanisms, remains controversial. Studies of fetal behavioural effects of antenatal corticosteroids (measured by biophysical profile and cardiotocograph) demonstrate up to 50% reduction in fetal movements at 24–48 hours, up to 90% reduction in fetal breathing movement at 48–72 hours, and decreased fetal heart rate variability of 20–30% at 24–72 hours. As these events (normally of clinical concern, particularly in the growth-restricted fetus) are seemingly happening concurrently with a restored UAEDF, it cannot be assumed the UAEDF restoration is beneficial. Additionally, animal studies have found that 1) blood-brain barrier alterations mean IUGR fetuses have longer exposure times to higher steroid concentrations 2) steroids may compromise their maintenance of blood pressure and cerebral blood flow. Clinically, a neonatal network registry study from 1991–96 found that steroids appeared to be equally of benefit to IUGR and non-IUGR fetuses. However, there are no randomised trials, and a more recent meta-analysis of several small case-control and cohort studies (excluding the registry trial) found that steroids did not confer benefits when given in IUGR. Whether or not steroids benefit IUGR fetuses as much as their normally grown counterparts, IUGR fetuses with abnormal UAEDF pre-steroids who do not respond to steroids by returning to positive UAEDF may be at increased risk for adverse outcome. Robertson, et al. found significantly higher levels of respiratory distress syndrome (RDS), chronic lung disease, and need for ventilation in 29 fetuses with no return of UAEDF post-steroids vs. 49 fetuses with return of UAEDF. Piazze, et al., in their study of 64 IUGR fetuses, reported a 67% RDS rate with persistent absent or reversed end diastolic flow (AREDf) after steroids and only a 20% rate if UAEDF returned. The current hypothesis is that fetuses with UAEDF return have sufficiently intact physiological mechanisms to respond to steroid challenge, while those with persistent UAEDF are a group with greater pre-existing compromise. This fits with Robertson et al.’s finding of lower cord pH at birth in their persistent AREDF group.

Differential effects of different corticosteroids?
The two most commonly used steroid preparations in clinical practice worldwide are betamethasone and dexamethasone. Current randomised data is inconclusive regarding whether either preparation has a decreased chance of long-term side effects while maintaining beneficial neonatal effects. There is scant published data on dexamethasone effects on fetal cardiovascular status as measured by ultrasound (Table 1), and only one study directly comparing women randomised to dexamethasone or betamethasone. In this study, only women with normal fetal pre-treatment flows were included, and a change in MCA but not UA flows was found with dexamethasone. In the few studies describing dexamethasone behavioural effects, only a minority of studies describe decreased fetal heart rate variability, body movement and breathing at 24–72 hours. This raises the possibility of different secondary (24+ hours after administration) effects of dexamethasone compared to betamethasone. The pharmaco-physiological mechanism behind any difference in effect is uncertain, but might relate either to timing of administration or absorption characteristics of long-acting betamethasone formulations.

The Myocardial Performance Index
An additional technique for ultrasound measurement of fetal cardiovascular status, without the expertise required to perform a full fetal echocardiogram, is the modified myocardial performance index (mod-MPI). In adults, the MPI distinguishes between normal and abnormal ventricular function, and has been extrapolated to evaluation of the fetal heart in both normal and complicated pregnancies. Our group has recently published a number of refinements to improve the repeatability of the mod-MPI, as well as producing Australian normal ranges for both left and right-sided mod-MPI.

As corticosteroid administration may alter fetal cardiac output, complicating the interpretation of mod-MPI in growth restricted or other complicated pregnancies where its use is currently being researched, it is important to document whether such changes occur. Apart from a small series of 5 IUGR and 5 control fetuses which found baseline cardiac strain in IUGR fetuses and transient improvement after steroids, we are not aware of published work systematically evaluating the effect of maternal corticosteroid administration on fetal mod-MPI.

Research gap and current study
Few studies have comprehensively assessed the short-term effect of antenatal corticosteroids on ultrasound and CTG measures of fetal cardiovascular function. There is likewise little data correlating short term fetal responses on ultrasound and CTG with either neonatal or infant outcome. There is also a research gap regarding effects of dexamethasone versus betamethasone.

The multicentre A*STEROID study (Australasian Antenatal Study To Evaluate the Role of Intramuscular Dexamethasone versus Betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability) is comparing the effects of betamethasone and dexamethasone in infants up to 2 years of age in a blinded, randomised trial. This study enables our group to concurrently assess, in a subgroup of A*STEROID patients, the short-term effects of:

1. Either corticosteroid on fetal and utero-placental hemodynamics, including cardiac function as measured by mod-MPI
2. Either steroid on fetal behavioural responses as measured by CTG and biophysical profile
3. Differential effects of betamethasone vs. dexamethasone
4. Correlation between short term effects and neonatal and infant outcomes.

Methods
Patients will be prospectively recruited as a sub-study of women participating in the multicentre randomised double-blind trial of antenatal intramuscular Betamethasone vs. Dexamethasone...
for women at risk of preterm birth < 34 weeks gestation, the A*STEROID trial. The sub-study acronym adopted is SUPER-
A*STEROID (Steroid Ultrasound Parameters Enhancing Routine-A*STEROID). SUPER-A*STEROID patients will be
recruited from two metropolitan Sydney hospitals participating in the A*STEROID study, the Royal Hospital for Women and St
George Hospital. Ethical approval for conduct of the study has been
granted by the local Human Research Ethics Committee
(SESLHD HREC 11/202).

Patients will be eligible for inclusion if they fulfil the A*STEROID study entry criteria of being at risk of preterm birth < 
34 weeks gestation, having a singleton or twin pregnancy, having
no contraindications to the use of antenatal corticosteroids, and
having given informed consent to participate in A*STEROID.

Additionally, for SUPER-A*STEROID entry, participants are
required to be aged 18–50, have had a normal fetal cardiac
morphology ultrasound, and give informed consent to
participate in SUPER-A*STEROID. Exclusion criteria are any of
the A*STEROID exclusion criteria (chorioamnionitis requiring
urgent delivery, higher order multiple pregnancy, antenatal
corticosteroids already given, known fetal lung maturation, or
in the second stage of labour), an abnormal cardiac morphology
scan, psychiatric illness precluding informed consent, insufficient
English for valid consent, or mothers taking digoxin or pure
beta-blocker. Use of maternal medications with minor potential
effects on the fetal cardiovascular system such as labetalol, will
be recorded but is not a reason for exclusion.

**Conduct of study**

All women who remain undelivered will have these
measurements repeated (with the exception of fetal growth
parameters and placental morphology) 24 hours after steroid
administration (acceptable range 18–30 hours), 48 hours after
steroid administration (acceptable range 42–54 hours), 96 hours
after steroid administration (acceptable range 3–5 days), and
7–10 days after steroid administration (if a repeat dose of steroids
was to be given, 7–10 day ultrasound was performed prior to the
repeat dose). Ultrasound machines used will be Voluson e8
(GE Medical Systems, Australia) at RHW site, and Voluson 730
(GE Medical Systems, Australia) or iU22 (Philips Healthcare,
Australia) at STG site. All MPI measurements will be performed
on Voluson e8 or Voluson 730 systems. Assessments will be
performed using 3.5–7- MHz linear or curved array transducers.

Following delivery, arterial and venous pH samples will be
obtained from the umbilical cord to allow correlation of
fetal status at delivery with previously noted ultrasound and
CTG parameters. Placentas will be sent for histopathological
examination. Pregnancy, labour, and neonatal data will be
abstracted from case notes.

**Data entry and analysis**

All data will be entered into an Excel spreadsheet and analysed
using SPSS (SPSS Inc, Chicago, IL, USA). As the normal
distribution of Doppler measurements changes with gestational
age, individual fetal measurements will be normalised prior to
analysis to give a Z-score (by expressing the deviation of the
individual measurements from the gestational age mean in
standard deviations). Mod-MPI values will be compared against
our previously published normal range. Analysis techniques for
repeated measures will be used to examine changes of Doppler
flows, MPI, biophysical profile, and CTG from baseline to the
follow-up ultrasounds.

All data will be collected and entered prior to unblinding of
investigators (projected to be January 2014) as to which steroid
was received. Relationships between Doppler parameters,
CTG, indication for steroid use, neonatal outcomes and
(after unblinding) type of steroid used will be analysed using
Pearson correlation. Continuous variables will be compared
using parametric or non-parametric analysis based on their
distribution. Proportional distributions of categorical outcome
variables will be related to CTG and Doppler results using Chi-
squared and Fisher's exact tests.

**Power and sample size**

Precision of the sample size calculation was limited by lack of
clarity regarding both expected effects of steroids in general on
fetal cardiovascular parameters, and any differential effect of
betamethasone vs. dexamethasone. A mean gestational age at
study entry of 31 weeks was used to allow use of assumptions
regarding likely population parameter means and standard
deviations from previous studies. All calculations of required
sample size were two-sided tests with alpha set at 0.05 and power
at a minimum of 80%.

Regarding whole group comparisons of pre-steroid and post-
steroid measurements, a sample size of 50 fetuses is proposed to
enable detections of

1. Decrease in short-term variability from 9 to 6–95% power
2. Decrease in proportion of normal variability traces from
   90% to 70%–95% power
3. Decrease in middle cerebral artery pulsatility index of 0.2
with a standard error of 0.4–90% power. Lesser sample size of 40 allows all these outcomes to be detected with at least 80% power. A smaller sample size of 20 is required in order to detect a change in MPI peak value of 10% (0.04) from the normal measurement of 0.42 ± 0.06 at 31 weeks, at 80% power. Regarding betamethasone vs. Dexamethasone comparisons, and allowing for the fact that numbers in each arm cannot be prospectively known and may not be balanced, a sample size of 40 fetuses is proposed to detect with 80% power:

1. A difference in MCA PI of 0.3 between the groups, assuming standard deviation of 0.3
2. A difference of 3 in mean short-term variability on CTG, assuming standard deviation of 3 in both groups.

Discussion
A substantial number of fetuses are exposed to corticosteroids due to their risk of being born prematurely. It is therefore important to understand short-term effects of corticosteroids on the fetus in utero, and whether there are correlations between these effects and neonatal outcomes and/or later outcomes. Also of importance is whether different steroid preparations display different effects on fetal hemodynamics. The A*STEROID trial of betamethasone vs. dexamethasone is providing the opportunity to comprehensively assess both the ultrasound-measured short term fetal hemodynamic and behavioural effects of these steroids in a blinded fashion, and their relationship to neonatal and later infant outcome. A total of 43 women and 47 fetuses were recruited to the SUPER-A*STEROID trial from Feb 2012–Jan 2013. Final results will be presented after unblinding of investigators to steroid group allocation.

Acknowledgements
The SUPER-A*STEROID study is generously supported by a research grant from the Australasian Society of Ultrasound in Medicine (ASUM).

The collaboration and assistance of Professor Caroline Crowther and the A*STEROID co-ordinating centre, in particular Pat Ashwood, in setting up the SUPER-A*STEROID study is gratefully acknowledged. The A*STEROID study is funded by the National Health and Medical Research Council (NHMRC).

Thank you to all medical, midwifery and sonology staff involved in recruitment for A*STEROID and SUPER-A*STEROID, particularly Anne Lainchbury at the Royal Hospital for Women, and Lynne Roberts and Karen Newell at St George Hospital.

References
1. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (review). Cochrane Database of Systematic Reviews 2010 (9).
2. Lee H, Lyndon A, Blumenfeld Y, Dudley R, Gould J. Antenatal steroid administration for premature neonates in california. Obstet Gynecol 2011; 117 (3): 603–09.
3. Mulder E, de Heus R, Visser G. Antenatal corticosteroids: short-term effects on fetal behaviour and haemodynamics. Semin Fetal Neonatal Med 2009; 14: 151–56.
4. Thuring A, Malcus P, Marsal K. Effect of maternal betamethasone on fetal and uteroplacental blood flow velocity waveforms. Ultrasound Obstet Gynecol 2011; 37: 668–72.
5. Piaze J, Anceschi M, Cerekja A, Cosmi E, Meloni P, Alberini A, et al. The combined effect of betamethasone and ritodrine on the middle cerebral artery in low risk third trimester pregnancies. J Perinat Med 2007; 35: 135–40.
6. Urban R, Lemancewicz A, Przepiesc J, Urban J, Kretowska M. Antenatal corticosteroid therapy: a comparative study of dexamethasone and betamethasone effects on fetal Doppler flow velocity waveforms. Eur J Obstet Gynecol Reprod Biol 2005; 120: 170–74.
7. Kahler C, Schleussner E, Moller A, Seewald HJ. Doppler measurements in fetoplacental vessels after maternal betamethasone administration. Fetal Diagn Ther 2004; 19: 52–57.
8. Wijnberger L, Bilardo C, Hecher K, Stigter G, Visser G. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet Gynecol 2004; 23: 584–89.
9. Simchen M, Alkazaleh F, Adamson S, Windrim R, Telford J, Beyene J, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190: 296–304.
10. Deren O, Kaira C, Onderoglu L, Yigit N, Durukan T, Bahado-Singh R. The effect of steroids on the biophysical profile and Doppler indices of umbilical and middle cerebral arteries in healthy preterm fetuses. Eur J Obstet Gynecol Reprod Biol 2001; 99: 72–76.
11. Piaze J, Anceschi M, La Torre R, Amici F, Maranghi L, Cosmi E. Effect of antenatal betamethasone therapy on maternal-fetal Doppler velocimetry. Early Hum Dev 2001; 60: 225–32.
12. Senat M, Ville Y. Effect of steroids on arterial Doppler in intrauterine growth retardation fetuses. Fetal Diagn Ther 2000; 15: 36–40.
13. Cohen B, Stigter R, Derks J, Mulder E, Visser G. Absence of significant haemodynamic changes in the uterus following maternal betamethasone administration. Ultrasound Obstet Gynecol 1996; 8: 252–55.
14. Meizner I, Katz M, Holchberg M, Mazor M, Insler V. Reduction or cessation of fetal movements after steroid administration for enhancement of lung maturation. II. Analysis of blood flow velocimetry. Isr J Med Sci 1989; 25: 556–59.
15. Chitrity Y, Caubel P, Herrero R, Schwinte A, Guillaumin D, Boulanger MC. Effects of maternal dexamethasone administration on fetal Doppler flow velocity waveforms. Br J Obstet Gynaecol 2000; 107: 501–07.
16. Rotmensch S, Liberati M, Vishne T, Celentano C, Ben-Rafael Z, Bellati U. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand 1999; 78: 493–500.
17. Piaze J, Comalli Dillon K, Cerekka A. Betamethasone effects on umbilical arteries and ductus venosus Doppler velocity waveforms in growth-restricted fetuses. J Matern Fetal Neonatal Med 2012; 25: 1179–82.
18. Nozaki A, Francisco R, Fonseca E, Miyadahira S, Zugaib M. Fetal hemodynamic changes following maternal betamethasone administration in pregnancies with fetal growth restriction and absent end-diastolic flow in the umbilical artery. Acta Obstet Gynecol Scand 2009; 88: 350–54.
19. Robertson M, Murila F, Tong S, Baker L, Yu V, Wallace E. Predicting perinatal outcome through changes in umbilical artery doppler studies after antenatal corticosteroids in the growth-restricted fetus. Obstet Gynecol 2009; 113: 636–40.
20. Muller T, Nanan R, Dietl J. Effect of antenatal corticosteroid administration on Doppler flow velocity parameters in pregnancies with absent or reverse end-diastolic flow in the umbilical artery. Acta Obstet Gynecol Scand 2003; 82: 794–96.
21. Edwards A, Baker T, Wallace E. Changes in umbilical artery flow velocity waveforms following maternal administration of betamethasone. Placenta 2003; 24: 12–16.
22 Edwards A, Baker T, Wallace E. Changes in fetoplacental vessel flow velocity waveforms following maternal administration of betamethasone. *Ultrasound Obstet Gynecol* 2002; 20: 240–44.
23 Wallace E, Baker L. Effect of antenatal betamethasone administration on placental vascular resistance. *Lancet* 1999; 353: 1404–07.
24 Wijnberger L, Bilardo C, Hecher K, Stigter R, Visser G. Antenatal betamethasone and fetoplacental blood flow (letter). *Lancet* 1999; 354: 256.
25 Barkehall-Thomas A, Thompson M, Baker L, Edwards A, Wallace E. Betamethasone associated changes in umbilical artery flow velocity waveforms in multiple pregnancies with umbilical artery absent end diastolic flow. *Aust N Z J Obstet Gynaecol* 2003; 43: 360–63.
26 Chang YL, Chang SD, Chao AS, Hsieh P, Wang CN, Wang TH. Fetal hemodynamic changes following maternal betamethasone administration in monochorionic twin pregnancies featuring one twin with selective growth restriction and abnormal umbilical artery Doppler. *J Obstet Gynaecol Res* 2011; 37: 1671–76.
27 Morrison J, Botting K, Soo P, McGillick E, Hiscock J, Zhang S, et al. Antenatal steroids and the IUGR fetus: Are Exposure and physiological effects on the lung and cardiovascular system the same as in normally grown fetuses? *J Pregnancy* 2012; 2012. Epub 2012 Nov 22.
28 Bernstein I, Horbar J, Badger G, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. *Am J Obstet Gynecol* 2000; 182: 198–206.
29 Torrance H, Derks J, Scherjon S, Wijnberger L, Visser G. Is antenatal steroid treatment effective in preterm IUGR fetuses? *Acta Obstet Gynecol Scand* 2009; 88: 1068–73.
30 Brownfoot F, Crowther C, Middleton P. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database of Systematic Reviews*. 2008 (4).
31 Meriki N, Izurieta A, Welsh A. Fetal left modified myocardial performance index: technical refinements in obtaining pulsed-Doppler waveforms. *Ultrasound Obstet Gynecol* 2012; 39 (4): 421–29.
32 Meriki N, Welsh AW. Technical considerations for measurement of the Fetal Left Modified Myocardial Performance Index. *Fetal Diagn Ther* 2012; 31: 76–80.
33 Meriki N, Welsh A. Development of Australian Reference Ranges for the Left Fetal Modified Myocardial Performance Index and the influence of caliper location on time interval measurement. *Fetal Diagn Ther* 2012; 32: 87–95.
34 Meriki N, Henry A, Welsh AW. Development of normal gestational ranges for the right myocardial performance index in the Australian population with 3 alternative caliper placements. *Ultrasound Obstet Gynecol* 2012; 40 (Suppl 1): 137.
35 Hodges R, Edwards A, Teoh M, Ramkrishna J, Wallace E. IUGR and betamethasone: blink and you’ll miss it. *Aust N Z J Obstet Gynaecol* 2011; 51: 472.
36 ANZCTR. Australasian Antenatal Study To Evaluate the Role Of Intramuscular Dexamethasone versus Betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability – a randomised controlled trial (trial registry entry Australian and New Zealand Clinical Trials registry). Australian and New Zealand Clinical Trials Registry; 2009. Available at https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12608000631303. Accessed March 2013.
37 Viero S, Chaddha V, Alkazaleh F, Simchen M, Malik A, Kelly E, et al. Prognostic value of placenta ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. *Placenta* 2004; 25: 735–41.